Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come

Executive Summary

GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in

You may also be interested in...



GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year

GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation

GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year

GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation

GSK Lamictal monotherapy for seizures

GlaxoSmithKline's Lamictal (lamotrigine) approved by FDA Jan. 14 for use as monotherapy in the treatment of partial seizures in patients 16 years and older. Originally approved in December 1996 as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, Lamictal has been part of GSK's plan to fill in its nearer-term pipeline through line extensions (1"The Pink Sheet" Dec. 15, 2003, p. 29)...

Related Content

UsernamePublicRestriction

Register

PS042986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel